Screener
Zevra Therapeutics, Inc. ZVRA Impairment of intangible assets
Discontinued — last reported Q3 '25
Impairment of intangible assets at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsFinitelived.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed November 5, 2025.
- Filed
- Nov 5, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001434647-25-000011
| Line item | Three months ended September 30, 2025 | Three months ended September 30, 2024 | Nine months ended September 30, 2025 | Nine months ended September 30, 2024 |
|---|---|---|---|---|
| Revenue, net | $26,063 | $3,695 | $72,345 | $11,569 |
| Cost of product revenue (excluding $315 and $1,545 in intangible asset amortization for the three months ended September 30, 2025, and 2024, respectively, and $3,546 and $4,619 in intangible asset amortization for the nine months ended September 30, 2025, and 2024, respectively, shown separately below) | 1,238 | 2,303 | 14,962 | 6,051 |
| Intangible asset amortization | 315 | 1,545 | 3,546 | 4,619 |
| Impairment of intangible assets | — | — | 58,710 | — |
| Operating expenses: | ||||
| Research and development | 3,432 | 10,945 | 10,123 | 33,743 |
| Selling, general and administrative | 16,935 | 16,208 | 57,262 | 38,743 |
| Total operating expenses | 20,367 | 27,153 | 67,385 | 72,486 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s impairment of intangible assets?
- Zevra Therapeutics, Inc. (ZVRA) reported impairment of intangible assets of $0 in Q3 2025.
- What does impairment of intangible assets mean?
- This represents a non-cash charge recognized when the carrying value of an intangible asset, such as acquired intellectual property or product rights, exceeds its fair value. It indicates a downward revision in the expected future economic benefits of specific drug programs or commercial assets. Investors monitor this to assess the recoverability of investments in research and development pipelines.
Ask your AI about Zevra Therapeutics, Inc.'s impairment of intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude